GLP-1 Drugs and Your Lungs: What a New Systematic Review Actually Found

You've heard about the nausea. The gastroparesis concerns. Maybe even the pancreatitis warnings. But here's something most GLP-1 users haven't thought about: what these drugs do to your lungs.

The News

A systematic review published June 19 in Cardiovascular Diabetology – Endocrinology Reports pulled together every study it could find on GLP-1 receptor agonists and respiratory adverse events. Nineteen studies made the cut: 4 randomized controlled trials (1,884 participants), 5 retrospective cohort studies (over 1.1 million patients), 3 pharmacovigilance analyses (nearly 500,000 adverse event reports), and 7 case reports.

The short version: for most people on semaglutide, tirzepatide, or similar drugs, the lung picture is mostly fine. But there are specific situations where the risk profile changes, and one of them matters a lot if you're heading into surgery.

The Data

The common stuff: no worse than placebo.

Upper respiratory tract infections showed up in two-thirds of the studies that tracked them. Colds, basically. But when researchers looked at the actual rates in controlled trials, GLP-1 users got URTIs at about the same rate as people on placebo. The GRADE certainty rating was moderate, meaning the evidence is reasonably solid. If you're on a GLP-1 and you catch a cold, the drug probably didn't cause it.

The pharmacovigilance signals: interesting but not conclusive.

Adverse event databases flagged disproportionate reporting of shortness of breath and asthma-like symptoms, particularly with exenatide. The reporting odds ratio was 2.14 (95% CI 1.88–2.43) in one analysis by Cazzola and colleagues. That number looks alarming until you understand what pharmacovigilance data actually means: these are voluntary reports, not controlled observations. People report what they notice, and when a drug is new and heavily prescribed, reporting goes up. These signals are hypothesis-generating. They tell researchers where to look next, not what's actually happening.

The rare serious events: real but very rare.

This is where things get specific. The review identified cases of anaphylaxis with bronchospasm (4 cases), acute eosinophilic pneumonia (1 case), perioperative aspiration pneumonitis (multiple cases across cohort studies), acute respiratory distress syndrome (2 cases, one fatal requiring ECMO life support), and spontaneous pneumomediastinum (1 case).

These events are real, documented in medical literature, and worth knowing about. They're also extremely rare relative to the millions of people taking GLP-1 RAs. The evidence certainty was rated very low, meaning we genuinely don't know how much of this is caused by the drug versus coincidence.

The plot twist: GLP-1 RAs might actually protect your lungs.

A large retrospective study by Henney and colleagues, covering 331,863 propensity-matched patients, found that GLP-1 receptor agonist users had a 40% lower risk of developing pneumonia compared to users of DPP-4 inhibitors. The hazard ratio was 0.60 (95% CI 0.58–0.62). The certainty was low because of the study design, but the signal was consistent and large.

This isn't as contradictory as it sounds. GLP-1 receptors exist in lung tissue, and there's preclinical evidence that GLP-1 signaling has anti-inflammatory effects in the respiratory system. The drug might simultaneously reduce pneumonia risk through anti-inflammatory mechanisms while creating rare adverse events through hypersensitivity reactions.

The One Thing That Actually Matters for Most People

Perioperative aspiration risk. This is the finding that should change behavior.

GLP-1 receptor agonists slow gastric emptying. That's part of how they work for weight loss: food stays in your stomach longer, you feel full sooner. But when you're under general anesthesia, a stomach that isn't empty is a serious problem. Stomach contents can travel up the esophagus and into the lungs, causing aspiration pneumonia, which can be life-threatening.

The RESIDUAL study, published June 10 in BMC Anesthesiology, looked at this directly. Researchers used gastric ultrasound to check stomach contents in patients before elective surgery. Even patients who had stopped their weekly GLP-1 injection for 7 or more days before surgery had increased residual gastric content 42% of the time, compared to 24% in the control group.

Think about that. A full week off the drug, and nearly half the patients still had more stomach contents than expected before surgery.

Anesthesiology societies are catching up. The American Society of Anesthesiologists has issued guidance suggesting extended fasting periods for GLP-1 RA users before procedures. But many surgeons and anesthesiologists still don't routinely ask about GLP-1 use, and many patients don't think to mention it.

If you're on semaglutide, tirzepatide, liraglutide, or any GLP-1 receptor agonist and you're scheduled for surgery, tell your anesthesiologist. Not your surgeon's office the day before. The anesthesiologist, ideally at your pre-op appointment. They may want to adjust your fasting protocol or use point-of-care gastric ultrasound to check your stomach before intubation.

The Exenatide Question

The review noted that exendin-4-based agents — exenatide (Byetta, Bydureon) and lixisenatide (Adlyxin) — appeared to carry the highest risk of hypersensitivity reactions. The likely reason: these drugs are derived from a protein found in Gila monster saliva. They're structurally different from human GLP-1 in ways that can trigger immune responses.

Semaglutide, tirzepatide, and liraglutide are modified versions of human GLP-1, which makes them less likely to provoke allergic reactions. If you're on exenatide and experiencing unexplained respiratory symptoms, this is worth discussing with your prescriber.

What This Review Actually Tells Us

The lead author, Ahuja, and colleagues at Maulana Azad Medical College in New Delhi were careful to frame this as signal detection, not causation proof. They used GRADE methodology, which is the gold standard for rating evidence quality. The findings break down like this:

• Common respiratory symptoms: essentially no different from placebo (moderate certainty)
• Dyspnoea and asthma signals: real but hypothesis-generating only (very low certainty)
• Rare serious events: documented but extremely rare (very low certainty)
• Pneumonia protection: possible but needs confirmation (low certainty)
• Aspiration risk during surgery: clinically actionable right now

The review doesn't tell you to stop taking your GLP-1 medication. It doesn't suggest the drugs are dangerous for your lungs in any routine sense. What it does is fill a gap: before this review, nobody had systematically pulled together the scattered evidence on GLP-1 RAs and respiratory health. Now we have a map, and the map shows that the territory is mostly safe with specific hazards worth knowing about.

Oria Take

This is exactly the kind of evidence we think matters. Not hype, not fear, not cherry-picked case reports used to generate clicks. A systematic review with transparent methodology, honest uncertainty quantification, and clinically actionable findings.

For Oria readers on GLP-1 receptor agonists: your lungs are probably fine. The common respiratory events tracked in trials are no different from placebo, and there's actually some evidence these drugs might protect against pneumonia. But if you're heading into surgery, this review is a clear signal to have a conversation with your anesthesiologist about your GLP-1 use and fasting protocols.

The exenatide hypersensitivity finding is worth noting for anyone on first-generation GLP-1 RAs. And the perioperative aspiration data is genuinely important for anyone scheduled for a procedure.

We'll keep tracking this as more data emerges. The review calls for prospective studies with pre-specified respiratory endpoints, and given how many people are now taking these drugs, that research is coming.

Evidence grade: B — Moderate certainty for common respiratory events; very low for rare serious events; low for pneumonia protection; clinically actionable for perioperative aspiration risk based on multiple converging evidence streams.

Sources

• Ahuja A, et al. "Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals." Cardiovasc Diabetol Endocrinol Rep. 2026 Jun 19;12(1):43. doi: 10.1186/s40842-026-00311-6

• Talmy T, et al. "Risk of postoperative respiratory complications in adults treated with GLP-1 receptor agonists." Br J Anaesth. 2026 May 29.

• Boudreau C, et al. "Residual gastric content after holding of GLP-1 RAs before elective surgery: the RESIDUAL study." BMC Anesthesiol. 2026 Jun 10.

• Tseng YT, et al. "Association of GLP-1 RAs with Mortality and Aspiration Pneumonia in Patients with Type 2 Diabetes After Gastrostomy." Int J Med Sci. 2026 Mar 17;23(4):1444-1455.

This article is for informational purposes only and does not constitute medical advice. The content is based on published research and is intended to help readers make informed decisions in consultation with their healthcare providers. Oria BioStack does not diagnose, treat, or recommend specific medical interventions. Always consult a qualified healthcare professional before making changes to your medication regimen or before surgical procedures.